

REMARKS

The present communication responds to the Office communication of January 24, 2007 in which the Examiner subjected claims 11-20 to a restriction requirement.

Claims 11-13 and 16-18 and 21 are pending in the application. Claims 14, 15, 19 and 20 have been cancelled. New claim 21 has been added. No new subject matter has been added to the claims.

Applicants note that the Examiner did not acknowledge new claims 21 and 22 from the response filed on October 31, 2006. However, this point is moot because Applicants are adding only new claim 21 in the present communication.

Restriction and Election of Claims

In the outstanding Office communication, three groups were identified:

- **Group I** (claims 11-13, 16-18) drawn to polynucleotides, vectors, host cells and methods of making a polypeptide;
- **Group II** (claims 14-15 and 20) drawn to a polypeptide and composition; and
- **Group III** (claim 19) drawn to an antibody.

Applicants hereby elect Group I, claims 11-13 and 16-18 *without traverse*.

New Claims

New claim 21 has been added, without adding new matter. Support can be found in general throughout the specification.

New claim 21 depends directly from independent claim 18 and incorporates all the limitations of claim 18. Therefore, claim 21 is encompassed in Group 1 for the same reasons as claim 18 and, further, in view of its additional recitations.

Conclusion

This paper should not generate any new fees, but the Commissioner is hereby authorized to charge any deficiencies and credit any overpayments associated with this paper to Deposit Account No. 04-1420.


It is respectfully submitted that claims 11-13, 16-18 and 21 are in condition for allowance. A Notice of Allowance is respectfully requested.

If a telephone conference would be helpful in resolving any remaining issues, please contact the undersigned at 612-340-7862.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

Date: February 21, 2007

By: 
Sean D. Solberg
Reg. No. 48,653